Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Entrada Therapeutics (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of its Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 on May 7, 2026.
The company will host an investor webcast and conference call at 8:30 a.m. ET; the webcast is available via the Investor Relations section of the company website and will be archived for 90 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TRDA
-57.27%2.0x vol
47 alerts
-57.27%Session close to close
+17.1%Peak Tracked
-66.3%Trough Tracked
$622.29MMarket Cap
2.0xRel. Volume
In the May 7 session, TRDA declined 57.27%, reflecting a significant negative market reaction.
Argus tracked a peak move of +17.1% during that session.
Argus tracked a trough of -66.3% from its starting point during tracking.
Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility.
Trading volume was above average at 2.0x the daily average, suggesting increased trading activity.
The stock dropped -57.3% in the session following this news. A negative reaction despite anticipatio...
Analysis
The stock dropped -57.3% in the session following this news. A negative reaction despite anticipation for Cohort 1 topline data would fit a pattern where broader portfolio or conference news previously saw weak price responses. Investors have faced event risk around ELEVATE‑44‑201 timelines, and the existence of a $400,000,000 shelf with a $150,000,000 ATM program may add overhang if markets worry about post-data financing, even before any actual usage occurs.
Key Figures
Topline results date:May 7, 2026Webcast time:8:30 a.m. ETReplay availability:90 days
Reported neuromuscular and ocular program progress and key 2026 milestones.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news around ELEVATE-44-201 and broader pipeline updates often saw modest positive price reactions, while conference-related headlines showed negative moves, indicating selective responses to different news types.
Recent Company History
Over the last few months, Entrada issued multiple updates linking directly to ELEVATE‑44‑201 and its broader RNA-based portfolio. A Feb 17 Data Monitoring Committee recommendation for a higher Cohort 2 dose and the Feb 26 earnings/clinical update both saw positive reactions, while conference and portfolio overviews on Jan 8 and Feb 4 drew negative responses. Today’s planned Cohort 1 topline announcement connects to those earlier dose-escalation and timeline disclosures.
Key Terms
duchenne muscular dystrophy, double-blind, placebo-controlled, multiple ascending dose, +3 more
7 terms
duchenne muscular dystrophymedical
"Cohort 1 of participants with Duchenne Muscular Dystrophy treated with ENTR-601-44"
A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.
double-blindmedical
"Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion"
A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.
placebo-controlledmedical
"Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
multiple ascending dosemedical
"double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2"
A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.
phase 1/2medical
"multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study"
Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.
investor webcasttechnical
"The Company will host an investor webcast and conference call at 8:30 a.m. ET"
An investor webcast is a live or archived online presentation where a company’s leaders share financial results, strategy and business updates directly with shareholders and analysts, often accompanied by slides and a question-and-answer segment. Like watching a live TV briefing, it helps investors judge management’s competence and clarify the story behind the numbers, and can change market expectations and a stock’s price.
q&atechnical
"Analysts planning to participate during the Q&A portion of the live call"
Q&A is a live or recorded session in which company leaders or spokespeople answer questions from investors, analysts, or journalists following presentations, earnings calls, or announcements. It matters to investors because the answers reveal management’s priorities, clarify numbers or plans, expose risks or opportunities, and often change market perceptions—similar to asking follow-up questions to judge how confident and consistent someone really is.
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results.
The webcast can be accessed by visiting the Investor Relations section of the Company’s website at www.entradatx.com. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here. The webcast will be archived and available for replay on the Entrada Therapeutics website for 90 days following the call.
About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
When will Entrada Therapeutics (TRDA) release ELEVATE-44-201 Cohort 1 topline results?
The company will announce Cohort 1 topline results on May 7, 2026. According to the company, the announcement covers the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 study.
How can investors access the Entrada Therapeutics (TRDA) webcast for the May 7, 2026 results?
Investors can access the live webcast via the company's Investor Relations website at www.entradatx.com. According to the company, the webcast will stream at 8:30 a.m. ET and include a live Q&A session.
Will Entrada Therapeutics (TRDA) provide a replay of the May 7, 2026 webcast and for how long?
Yes, the webcast will be archived for replay on the company website for 90 days. According to the company, the archived webcast will be available in the Investor Relations section after the live call.
What part of the ELEVATE-44-201 study does the May 7, 2026 announcement cover for TRDA?
The announcement covers Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of Phase 1/2. According to the company, these are topline results from that specific cohort.
How can analysts join the Entrada Therapeutics (TRDA) Q&A during the May 7, 2026 call?
Analysts planning to participate can join the conference call using the company's provided audio-conferencing link. According to the company, Q&A participation details are available with the webcast and call instructions.
What time is Entrada Therapeutics (TRDA) scheduled to discuss ENTR-601-44 results on May 7, 2026?
The investor webcast and conference call are scheduled for 8:30 a.m. ET on May 7, 2026. According to the company, the live event will include management discussion of topline Cohort 1 results.
